{"id":"https://openalex.org/W4408599836","doi":"https://doi.org/10.1016/j.farma.2025.02.006","title":"[Art\u00edculo traducido] An\u00e1lisis costes-efectividad del tocilizumab biosimilar subcut\u00e1neo en pacientes con artritis reumatoide en Espa\u00f1a","display_name":"[Art\u00edculo traducido] An\u00e1lisis costes-efectividad del tocilizumab biosimilar subcut\u00e1neo en pacientes con artritis reumatoide en Espa\u00f1a","publication_year":2025,"publication_date":"2025-03-19","ids":{"openalex":"https://openalex.org/W4408599836","doi":"https://doi.org/10.1016/j.farma.2025.02.006","pmid":"https://pubmed.ncbi.nlm.nih.gov/40113553"},"language":"es","primary_location":{"id":"doi:10.1016/j.farma.2025.02.006","doi":"https://doi.org/10.1016/j.farma.2025.02.006","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.farma.2025.02.006","pdf_url":null,"source":{"id":"https://openalex.org/S120921240","display_name":"Farmacia Hospitalaria","issn_l":"1130-6343","issn":["1130-6343","2171-8695"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","latindex","medline","poland-40"],"host_organization":"https://openalex.org/P4310322529","host_organization_name":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria","host_organization_lineage":["https://openalex.org/P4310322529"],"host_organization_lineage_names":["Sociedad Espa\u00f1ola de Farmacia Hospitalaria"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Farmacia Hospitalaria","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1016/j.farma.2025.02.006","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033544814","display_name":"Fernando P\u00e9rez-Ruiz","orcid":"https://orcid.org/0000-0002-5268-1894","observed_orcids":["https://orcid.org/0000-0002-5268-1894"]},"institutions":[{"id":"https://openalex.org/I4210125364","display_name":"Osakidetza","ror":"https://ror.org/02g7qcb42","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210125364"]},{"id":"https://openalex.org/I4210137412","display_name":"Hospital de Cruces","ror":"https://ror.org/03nzegx43","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210125364","https://openalex.org/I4210137412"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Fernando P\u00e9rez-Ruiz","raw_affiliation_strings":["Chief of Rheumatology Division, Osakidetza, OSI-EEC, Cruces University Hospital, Barakaldo, Bizkaia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chief of Rheumatology Division, Osakidetza, OSI-EEC, Cruces University Hospital, Barakaldo, Bizkaia, Spain","institution_ids":["https://openalex.org/I4210125364","https://openalex.org/I4210137412"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090353686","display_name":"Carlos Crespo-Diz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158603","display_name":"Complejo Hospitalario de Pontevedra","ror":"https://ror.org/016cxc226","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210158603"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Carlos Crespo-Diz","raw_affiliation_strings":["Chief of Hospital Pharmacy Department, \u00c1rea Sanitaria Pontevedra e O Saln\u00e9s / Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chief of Hospital Pharmacy Department, \u00c1rea Sanitaria Pontevedra e O Saln\u00e9s / Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain","institution_ids":["https://openalex.org/I4210158603"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027189216","display_name":"Joan Antoni Schoenenberger-Arnaiz","orcid":"https://orcid.org/0000-0002-8563-8358","observed_orcids":["https://orcid.org/0000-0002-8563-8358"]},"institutions":[{"id":"https://openalex.org/I15766328","display_name":"Universitat de Lleida","ror":"https://ror.org/050c3cw24","country_code":"ES","type":"education","lineage":["https://openalex.org/I15766328"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Joan Antoni Schoenenberger-Arnaiz","raw_affiliation_strings":["Chief of Pharmacy Department, Regi\u00f3 Sanit\u00e0ria de Lleida, Lleida, Spain; Universitat de Lleida, Lleida, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chief of Pharmacy Department, Regi\u00f3 Sanit\u00e0ria de Lleida, Lleida, Spain; Universitat de Lleida, Lleida, Spain","institution_ids":["https://openalex.org/I15766328"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065117099","display_name":"M\u00f3nica Cerezales","orcid":"https://orcid.org/0000-0001-6705-006X","observed_orcids":["https://orcid.org/0000-0001-6705-006X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M\u00f3nica Cerezales","raw_affiliation_strings":["Axentiva Solutions S.L., Oviedo, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Axentiva Solutions S.L., Oviedo, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069697084","display_name":"Carlos Crespo","orcid":"https://orcid.org/0000-0001-6066-0818","observed_orcids":["https://orcid.org/0000-0001-6066-0818"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carlos Crespo","raw_affiliation_strings":["Axentiva Solutions S.L., Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Axentiva Solutions S.L., Barcelona, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069602249","display_name":"Marcelo Alejandro Guigini","orcid":"https://orcid.org/0009-0008-3718-5180","observed_orcids":["https://orcid.org/0009-0008-3718-5180"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marcelo Alejandro Guigini","raw_affiliation_strings":["Fresenius Kabi Espa\u00f1a, S.A.U, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fresenius Kabi Espa\u00f1a, S.A.U, Barcelona, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106246065","display_name":"Jos\u00e9 Ignacio Peinado-Fabregat","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Ignacio Peinado-Fabregat","raw_affiliation_strings":["Fresenius Kabi Espa\u00f1a, S.A.U, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fresenius Kabi Espa\u00f1a, S.A.U, Barcelona, Spain","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047882021","display_name":"M\u00f3nica Climente Mart\u00ed","orcid":"https://orcid.org/0000-0002-4387-1987","observed_orcids":["https://orcid.org/0000-0002-4387-1987"]},"institutions":[{"id":"https://openalex.org/I4210126200","display_name":"Hospital Universitario Doctor Peset","ror":"https://ror.org/03971n288","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210126200"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"M\u00f3nica Climente-Mart\u00ed","raw_affiliation_strings":["Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address: climente_mon@gva.es"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address: climente_mon@gva.es","institution_ids":["https://openalex.org/I4210126200"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5047882021"],"corresponding_institution_ids":["https://openalex.org/I4210126200"],"apc_list":{"value":1640,"currency":"USD","value_usd":1640},"apc_paid":{"value":1640,"currency":"USD","value_usd":1640},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"49","issue":"5","first_page":"T278","last_page":"T285"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.6934000253677368,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.6934000253677368,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.28859999775886536,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9179999828338623},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9430000185966492},{"id":"https://openalex.org/keywords/subcutaneous-tocilizumab","display_name":"subcutaneous tocilizumab","score":0.9589999914169312},{"id":"https://openalex.org/keywords/disease-modifying-antirheumatic-drugs","display_name":"disease-modifying antirheumatic drugs","score":0.843999981880188},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8600000143051147},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7990000247955322},{"id":"https://openalex.org/keywords/remission","display_name":"remission","score":0.7319999933242798},{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":0.8999999761581421},{"id":"https://openalex.org/keywords/certolizumab","display_name":"certolizumab","score":0.9309999942779541},{"id":"https://openalex.org/keywords/upadacitinib","display_name":"upadacitinib","score":0.953000009059906},{"id":"https://openalex.org/keywords/sarilumab","display_name":"sarilumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.5249999761581421},{"id":"https://openalex.org/keywords/spain","display_name":"Spain","score":0.7440000176429749}],"concepts":[{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.8269298076629639},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.764898419380188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1876034438610077}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.farma.2025.02.006","doi":"https://doi.org/10.1016/j.farma.2025.02.006","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.farma.2025.02.006","pdf_url":null,"source":{"id":"https://openalex.org/S120921240","display_name":"Farmacia Hospitalaria","issn_l":"1130-6343","issn":["1130-6343","2171-8695"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","latindex","medline","poland-40"],"host_organization":"https://openalex.org/P4310322529","host_organization_name":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria","host_organization_lineage":["https://openalex.org/P4310322529"],"host_organization_lineage_names":["Sociedad Espa\u00f1ola de Farmacia Hospitalaria"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Farmacia Hospitalaria","raw_type":"journal-article"},{"id":"pmid:40113553","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40113553","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.farma.2025.02.006","doi":"https://doi.org/10.1016/j.farma.2025.02.006","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.farma.2025.02.006","pdf_url":null,"source":{"id":"https://openalex.org/S120921240","display_name":"Farmacia Hospitalaria","issn_l":"1130-6343","issn":["1130-6343","2171-8695"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","latindex","medline","poland-40"],"host_organization":"https://openalex.org/P4310322529","host_organization_name":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria","host_organization_lineage":["https://openalex.org/P4310322529"],"host_organization_lineage_names":["Sociedad Espa\u00f1ola de Farmacia Hospitalaria"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Farmacia Hospitalaria","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1617328014","https://openalex.org/W2070400812","https://openalex.org/W2103853363","https://openalex.org/W2120075987","https://openalex.org/W2132647986","https://openalex.org/W2501112626","https://openalex.org/W2607078264","https://openalex.org/W2767727558","https://openalex.org/W2930875443","https://openalex.org/W2997221351","https://openalex.org/W3013237363","https://openalex.org/W3023751647","https://openalex.org/W3081904877","https://openalex.org/W3092849554","https://openalex.org/W3112197686","https://openalex.org/W3198961522","https://openalex.org/W4322773713","https://openalex.org/W4324311329","https://openalex.org/W4387030217","https://openalex.org/W4400039069","https://openalex.org/W4400741621"],"related_works":["https://openalex.org/W4405394714","https://openalex.org/W2587823592","https://openalex.org/W4405748271","https://openalex.org/W7047048229","https://openalex.org/W4401170300","https://openalex.org/W7139417037","https://openalex.org/W2412309810","https://openalex.org/W4241885356","https://openalex.org/W2076254751","https://openalex.org/W2078168118"],"abstract_inverted_index":{"La":[0,54],"artritis":[1],"reumatoide":[2],"(AR)":[3],"es":[4,76],"la":[5,35,93,111,120,135,161,184,191,215,272,277,296],"enfermedad":[6,36],"reum\u00e1tica":[7],"inflamatoria":[8],"cr\u00f3nica":[9],"m\u00e1s":[10,274,305],"com\u00fan,":[11],"y":[12,15,28,127,142,146,166,180,201,233,245,249,255,264,295,323],"su":[13,51],"manejo":[14],"morbilidad":[16],"suponen":[17],"una":[18,130,320],"gran":[19],"carga":[20],"para":[21,41,182,196,231,237,243,247,257],"los":[22,42,46,57,138,167,187,225,258,303],"sistemas":[23],"de":[24,30,34,56,68,80,97,103,109,116,119,137,151,160,163,168,170,177,186,199,204,217,279,284,293,298,330],"salud.":[25,98],"El":[26,74,211,260],"desarrollo":[27],"uso":[29,52],"f\u00e1rmacos":[31],"antirreum\u00e1ticos":[32],"modificadores":[33],"han":[37,49],"contribuido":[38],"a":[39,70,224,290,300,359,423,433,618],"mejoras":[40],"pacientes,":[43],"sin":[44],"embargo,":[45],"altos":[47],"costes":[48,156],"impedido":[50],"generalizado.":[53],"aparici\u00f3n":[55],"biosimilares":[58],"est\u00e1":[59],"cambiando":[60],"este":[61],"paradigma":[62],"al":[63],"ofrecer":[64],"el":[65,78,197,202,288,328],"mismo":[66],"perfil":[67],"beneficio-riesgo":[69],"un":[71,101,106],"menor":[72],"coste.":[73],"objetivo":[75],"analizar":[77],"coste-efectividad":[79,193],"tocilizumab":[81,413,548],"biosimilar":[82,412],"(bsTCZ)":[83,414],"subcut\u00e1neo":[84],"en":[85,90,140,144,262,276,313,327,334,336],"pacientes":[86,331],"con":[87,105,149,251,332,338],"AR":[88,333],"moderada-severa":[89],"Espa\u00f1a":[91,335],"desde":[92],"perspectiva":[94],"del":[95],"sistema":[96],"Se":[99,174,189],"desarroll\u00f3":[100],"modelo":[102],"Markov":[104,428],"horizonte":[107],"temporal":[108],"toda":[110,214],"vida":[112,205,216],"incluyendo":[113],"cinco":[114],"estados":[115],"salud:":[117],"remisi\u00f3n":[118,200],"enfermedad;":[121],"actividad":[122],"baja,":[123],"moderada":[124,301],"o":[125,271,311],"alta;":[126],"muerte.":[128],"Mediante":[129],"b\u00fasqueda":[131],"PICO-S-T":[132,452],"se":[133,147,158],"identific\u00f3":[134],"eficacia":[136],"tratamientos":[139],"metan\u00e1lisis":[141,143],"red,":[145],"complement\u00f3":[148],"evidencia":[150],"ensayos":[152],"cl\u00ednicos":[153],"publicados.":[154],"Los":[155,239,282],"farmacol\u00f3gicos":[157],"obtuvieron":[159],"base":[162],"datos":[164],"BotPlus,":[165],"recursos":[169],"las":[171,280,315,339],"tarifas":[172],"regionales.":[173],"realizaron":[175],"an\u00e1lisis":[176,283],"sensibilidad":[178,285],"determin\u00edsticos":[179],"probabil\u00edsticos":[181],"validar":[183],"robustez":[185],"resultados.":[188],"calcul\u00f3":[190],"ratio":[192,501],"incremental":[194],"(RCEI)":[195],"coste/porcentaje":[198],"coste/a\u00f1os":[203],"ganados":[206],"ajustados":[207],"por":[208],"calidad":[209],"(AVAC).":[210],"coste":[212,289],"durante":[213],"bsTCZ":[218,268,294,308,317,518,565,584,604,614],"fue":[219,269,309],"183.741\u20ac":[220],"(m\u00e1s":[221,235],"bajo)":[222],"frente":[223],"comparativos":[226],"que":[227,267,287,324],"oscilaban":[228],"entre":[229,253],"184.317\u20ac":[230],"infliximab":[232,531],"201.972\u20ac":[234],"alto)":[236],"certolizumab.":[238,537],"AVAC":[240],"fueron":[241,302],"13,74":[242],"upadacitinib":[244,542],"13,73":[246],"sarilumab":[248,546],"tocilizumab,":[250],"valores":[252],"13,53":[254],"13,72":[256],"comparadores.":[259],"RCEI":[261],"\u20ac/remisi\u00f3n":[263],"\u20ac/AVAC":[265],"mostraron":[266,286],"dominante":[270,310],"alternativa":[273,321],"coste-efectiva":[275,322],"mayor\u00eda":[278],"comparaciones.":[281,316],"largo":[291],"plazo":[292],"transici\u00f3n":[297],"baja":[299],"factores":[304],"influyentes.":[306],"Adem\u00e1s,":[307],"coste-efectivo":[312],"todas":[314],"demostr\u00f3":[318],"ser":[319],"genera":[325],"ahorros":[326],"tratamiento":[329],"comparaci\u00f3n":[337],"alternativas":[340],"terap\u00e9uticas":[341],"disponibles.":[342],"Rheumatoid":[343],"arthritis":[344],"(RA)":[345],"is":[346,391,405],"the":[347,408,442,476,495,556,572,575,599,612,624,636],"most":[348,570,576,600],"common":[349],"chronic":[350],"inflammatory":[351],"rheumatic":[352],"disease,":[353],"its":[354],"management":[355],"and":[356,366,400,449,460,463,479,487,507,543,547,553,561,588,620],"morbidity":[357],"impose":[358],"great":[360],"burden":[361],"to":[362,376,386,406,493,532,592,616,634],"healthcare":[363,424],"systems.":[364],"Development":[365],"rollout":[367],"of":[368,410,441,456,497,505,517,571,626],"biological":[369],"disease":[370,594],"modifying":[371],"anti-rheumatic":[372],"drugs":[373],"has":[374],"contributed":[375],"improvements":[377],"for":[378,415,503,530,536,541,545,555,623],"patients,":[379],"however,":[380],"high":[381,447],"costs":[382,472,482,525],"have":[383],"prevented":[384],"them":[385],"be":[387,617],"widely":[388],"used.":[389],"This":[390],"being":[392],"addressed":[393],"with":[394,396,417,432,467,549,628],"biosimilars,":[395],"equal":[397],"benefit\u2013risk":[398],"profile":[399],"reduced":[401],"costs.":[402],"The":[403,579],"objective":[404],"analyze":[407],"cost-effectiveness":[409,500],"subcutaneous":[411],"patients":[416,627],"moderate\u2013severe":[418],"RA":[419,629],"in":[420,458,569,610,630],"Spain":[421,631],"from":[422,475,483,527,590],"system":[425],"perspective.":[426],"A":[427,451],"model":[429],"was":[430,464,519,566,605],"developed":[431],"lifetime":[434],"horizon":[435],"including":[436],"5":[437],"health":[438,596],"states:":[439],"remission":[440,506],"disease;":[443],"low,":[444],"moderate,":[445],"or":[446,574,608],"activity;":[448],"death.":[450],"search":[453],"retrieved":[454],"efficacy":[455],"treatments":[457],"meta-analysis":[459],"network":[461],"meta-analysis,":[462],"further":[465],"complemented":[466],"published":[468],"clinical":[469],"trials.":[470],"Pharmacological":[471],"were":[473,491,513,539,598],"obtained":[474],"BotPlus":[477],"database,":[478],"medical":[480],"resources":[481],"regional":[484],"tariffs.":[485],"Deterministic":[486],"probabilistic":[488],"sensitivity":[489,580],"analysis":[490,581],"performed":[492],"validate":[494],"robustness":[496],"results.":[498],"Incremental":[499],"(ICER)":[502],"cost/percentage":[504],"cost/quality-adjusted":[508],"life":[509],"year":[510],"(QALY)":[511],"gain":[512],"calculated.":[514],"Lifetime":[515],"cost":[516],"183":[520],"741\u20ac":[521],"(lowest)":[522],"versus":[523],"comparative":[524],"ranging":[526],"184":[528],"317\u20ac":[529],"201":[533],"972\u20ac":[534],"(highest)":[535],"QALYs":[538],"13.74":[540],"13.73":[544],"values":[550],"between":[551],"13.53":[552],"13.72":[554],"comparators.":[557],"ICERs":[558],"as":[559],"\u20ac/remission":[560],"\u20ac/QALY":[562],"showed":[563,582],"that":[564,583],"either":[567,606],"dominant":[568,607],"comparisons":[573],"cost-effective":[577,609,619],"alternative.":[578],"long":[585],"term":[586],"cost,":[587],"transition":[589],"low":[591],"moderate":[593],"activity":[595],"status":[597],"influential":[601],"factors.":[602],"Moreover,":[603],"all":[611,635],"comparisons.":[613],"demonstrated":[615],"cost-saving":[621],"alternative":[622],"treatment":[625],"when":[632],"compared":[633],"available":[637],"therapeutic":[638],"alternatives.":[639]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-03-20T00:00:00"}